

INTRODUCTION .....	xx
CONTRIBUTION OF THE STUDY AND FOR WHOM .....	xx
OBJECTIVES AND GOALS OF THE STUDY .....	xx
STUDY SCOPE AND FORMAT .....	xxi
METHODOLOGY .....	xxii
INFORMATION SOURCES .....	xxii
AUTHOR'S CREDENTIALS .....	xxii
RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS .....	xxii
BCC ONLINE SERVICES .....	xxiii
DISCLAIMER .....	xxiv
 EXECUTIVE SUMMARY .....	 xxv
<i>SUMMARY TABLE GLOBAL MARKET FORECAST FOR         IMMUNOTHERAPIES TO TREAT CANCER, THROUGH 2012 (\$         MILLIONS)</i> .....	   XXVI
<i>SUMMARY FIGURE GLOBAL MARKET FORECAST FOR         IMMUNOTHERAPIES TO TREAT CANCER, 2005-2012 (\$         MILLIONS)</i> .....	   XXVI
 OVERVIEW .....	 1
DEFINITION AND ETIOLOGY OF Cancer .....	1
CANCER STATISTICS .....	2
<i>TABLE 1 PROBABILITY OF DEVELOPING SELECTED INVASIVE         CANCERS, BY SEX, BASED ON CANCER CASES DIAGNOSED IN         2000 AND 2002 (%)</i> .....	   2
<i>TABLE 2 INCIDENCE, MORTALITY AND SURVIVAL RATES FOR         COMMON CANCERS IN THE U.S., 2006</i> .....	   3
<i>TABLE 3 CANCER PREVALENCE RATES IN THE U.S., 2003*</i> .....	3
<i>TABLE 3 (CONTINUED)</i> .....	4
IMMUNOTHERAPY OF CANCER .....	5
TYPES OF CANCER FOR WHICH IMMUNOTHERAPY TREATMENTS EXIST OR ARE LIKELY TO BE INTRODUCED BY 2012 .....	   5
BREAST CANCER .....	5
COLORECTAL CANCER .....	6
HEAD AND NECK CANCER .....	6
KIDNEY CANCER .....	6
LEUKEMIAS .....	6
Leukemias (Continued) .....	7
LIVER CANCER .....	8
LUNG CANCER .....	8
MALIGNANT MELANOMA .....	9
MULTIPLE MYELOMA .....	9

NONHODGKIN'S LYMPHOMA .....	10
OSTEOSARCOMA .....	10
OVARIAN CANCER .....	10
PANCREATIC CANCER .....	11
PROSTATE CANCER .....	11
STOMACH CANCER.....	12
CURRENT METHODS OF TREATMENT .....	12
SURGERY .....	12
RADIATION THERAPY .....	13
PHARMACEUTICAL THERAPY .....	13
IMMUNOTHERAPY .....	14
INFLAMMATORY RESPONSE .....	14
Cell-Mediated Immunity .....	14
Humoral Immunity.....	15
Macrophage Processing.....	15
Nonspecific Immunity .....	15
CYTOKINES .....	16
Two Types of Cytokines.....	16
MONOCYTES.....	16
PHAGOCYTES .....	17
SPECIFIC IMMUNITY.....	17
Lymphocytes .....	17
B-Cells .....	18
T-Cells .....	18
NK Cells .....	18
CLINICAL APPROACHES TO IMMUNOTHERAPY.....	18
Passive Cellular Immunotherapy .....	19
Dealing with Significant Toxicity.....	19
Passive Humoral Immunotherapy .....	19
Active Specific Immunotherapy .....	19
Nonspecific Immunotherapy .....	20
TYPES OF IMMUNOTHERAPY PRODUCTS .....	20
Biological Response Modifiers.....	20
<i>TABLE 4 COLONY STIMULATING FACTORS AND</i>	
<i>ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR</i>	
<i>EFFECTS .....</i>	<i>21</i>
<i>TABLE 5 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR</i>	
<i>EFFECTS .....</i>	<i>21</i>
<i>TABLE 6 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR</i>	
<i>EFFECTS .....</i>	<i>22</i>
<i>TABLE 6 (CONTINUED).....</i>	<i>23</i>
<i>TABLE 7 TUMOR NECROSIS FACTORS, THEIR NATURAL</i>	
<i>SOURCES, AND MAJOR EFFECTS .....</i>	<i>24</i>
Colony Stimulating Factors .....	24

Treating Neutropenic Fevers .....	24
A Justified Expense .....	25
Interferons .....	25
A Family of Small Proteins .....	26
Anticancer Effects.....	26
Side Effects.....	27
Production of Interferon .....	27
Interferon-alpha.....	27
Interferon-beta .....	28
Interferon-Beta-1a .....	28
Interleukins .....	28
Interleukin-2 .....	28
Other Infection-Fighting Cells .....	29
Side Effects.....	29
Tumor Necrosis Factor .....	30
ANTIBODIES.....	30
ANTIBODY FORMS IN PRODUCTS .....	31
Abtides .....	31
Antibody Conjugates .....	31
Antiserums.....	32
Bispecific Antibodies .....	32
Camouflaged Antibodies.....	32
Chimeric Antibodies .....	33
Humanized Antibodies .....	34
Fully Human Antibodies .....	35
Progenitor Stem Cells.....	35
Single-Chain Antibodies.....	36
Synthetic Antibodies .....	37
VACCINES.....	38
ANTIGENS: THEIR ROLE IN CANCER VACCINES.....	38
VACCINE DEVELOPMENT STRATEGIES .....	38
A SUMMARY OF TWO APPROACHES: LOW-TECH VS. HIGH-TECH.....	39
TECHNOLOGY ADVANCES .....	39
PRODUCTS AND APPLICATIONS .....	40
IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006 .....	40
<i>TABLE 8 IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006</i> .....	40
MECHANISM OF ACTION OF SELECTED IMMUNOTHERAPY PRODUCTS .....	41
<i>TABLE 9 MOLECULAR TARGET(S), MECHANISM(S) OF ACTION AND CANCER(S) TARGETED BY LEADING IMMUNOTHERAPY PRODUCTS</i> .....	41

BIOLOGICAL RESPONSE MODIFIERS.....	41
THE MARKET FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER.....	42
<i>TABLE 10 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, THROUGH 2012 (\$ MILLIONS)</i> .....	42
<i>FIGURE 1 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, 2005-2012 (\$ MILLIONS)</i> .....	42
COLONY STIMULATING FACTORS .....	43
MARKETED BRM PRODUCTS FOR THE TREATMENT OF CANCER.....	43
<i>TABLE 11 COLONY-STIMULATING FACTOR PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER</i> .....	43
Aranesp .....	44
Granocyte .....	44
Leukine.....	44
Neorecormon .....	44
Neulasta/Neupopeg/Neupogen/Granulokine .....	45
Neumega .....	46
Procrit.....	46
Stemgen.....	46
The Market for Colony Stimulating Factors .....	47
<i>TABLE 12 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS IN CANCER TREATMENT BY PRODUCT, THROUGH 2012 (\$ MILLIONS)</i> .....	47
The Market for Colony Stimulating Factors to Treat Cancer .....	48
<i>TABLE 13 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 (\$ MILLIONS)</i> .....	48
<i>FIGURE 2 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 (\$ MILLIONS)</i> .....	48
Colony Stimulating Factors in Development .....	49
INTERFERONS .....	49
Interferon-Alpha .....	49
Interferon Alpha-2b Products.....	49
Marketed Interferon Products for the Treatment of Cancer .....	50
<i>TABLE 14 INTERFERON PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER</i> .....	50
Infergen .....	50
Intron A and PEG-Intron/Rebetron .....	50

□ PEG-Intron vs. Intron A .....	51
Multiferon.....	52
Roferon-A.....	52
Interferon-Gamma.....	53
Actimmune/Imukin.....	53
The Market for Interferon Products Used in the Treatment of Cancer .....	53
<i>TABLE 15 GLOBAL MARKET FORECAST FOR INTERFERON ALPHA AND GAMMA PRODUCTS* USED IN THE TREATMENT OF CANCER BY PRODUCT, THROUGH 2012 (\$ MILLIONS)</i> .....	53
THE MARKET FOR INTERFERONS TO TREAT CANCER.....	54
<i>TABLE 16 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 (\$ MILLIONS)</i> .....	54
<i>FIGURE 3 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 (\$ MILLIONS)</i> .....	54
INTERLEUKINS .....	55
Marketed Interleukin Products for the Treatment of Cancer .....	55
<i>TABLE 17 INTERLEUKIN PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER</i> .....	55
ONTAK.....	55
PROLEUKIN .....	56
The Market for Interleukin Products for the Treatment of Cancer .....	56
<i>TABLE 18 GLOBAL MARKET FORECAST FOR INTERLEUKINS IN THE TREATMENT OF CANCER, BY PRODUCT, THROUGH 2012 (\$ MILLIONS)</i> .....	57
Product .....	57
TUMOR NECROSIS FACTOR INHIBITORS .....	57
BIOLOGICAL RESPONSE MODIFIERS IN DEVELOPMENT FOR THE TREATMENT OF CANCER .....	57
<i>TABLE 19 SELECTED BIOLOGICAL RESPONSE MODIFIERS IN PHASE III OR LATER DEVELOPMENT</i> .....	58
Actimmune.....	58
Cintrekeidin Besudotox .....	59
Multikine.....	59
Clinical Trial Results.....	59
A Coca-Cola Formula.....	60
PEG-Intron .....	60
PRX321.....	60
Virulizin .....	60
COMBINATION CYTOKINE-ANTIBODY TECHNOLOGY IN DEVELOPMENT.....	61
MONOCLONAL ANTIBODY PRODUCTS .....	62

<i>TABLE 20 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER: U.S.</i> .....	62
<i>TABLE 20 (CONTINUED)</i> .....	63
MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER.....	63
Avastin .....	63
Avastin (Continued).....	64
Avastin (Continued).....	65
The Avastin Advantage .....	66
Medicare Reimbursement Law Supports Use of Avastin .....	66
Bexxar .....	67
Bexxar (Continued).....	68
Campath/MabCampath.....	69
Erbix .....	70
<i>TABLE 21 RANGE OF EGFR EXPRESSION IN SOLID TUMORS</i> .....	70
<i>TABLE 22 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES</i> .....	71
Erbix (Continued).....	72
Herceptin .....	73
Mylotarg.....	74
Panorex .....	75
Rituxan/MabThera .....	75
Rituxan/Mabthera (Continued).....	76
Vectibix .....	77
Zevalin.....	78
First Radioimmunotherapeutic Drug .....	78
Results of Trials .....	79
Sales of Zevalin .....	80
THE MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR ALL INDICATIONS.....	80
Monoclonal Antibody Sales by Technology.....	81
<i>TABLE 23 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, THROUGH 2012 (\$ MILLIONS)</i> .....	81
<i>FIGURE 4 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, 2005-2012 (\$ MILLIONS)</i> .....	82
Monoclonal Antibody Sales by Target .....	82
<i>TABLE 24 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET, THROUGH 2012 (\$ MILLIONS)</i> .....	83
THE MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES TO TREAT CANCER.....	83

<i>TABLE 25 GLOBAL MARKET FORECAST FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 (\$ MILLIONS)</i> .....	83
<i>TABLE 25 (CONTINUED)</i> .....	84
THE EUROPEAN MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES .....	84
<i>TABLE 26 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET FOR THE TREATMENT OF CANCER</i> .....	84
<i>TABLE 27 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 (\$ MILLIONS)</i> .....	85
<i>FIGURE 5 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, 2005-2012 (\$ MILLIONS)</i> .....	85
MONOCLONAL ANTIBODY PRODUCTS IN DEVELOPMENT FOR THE treatment of cancer .....	86
<i>TABLE 28 SELECTED MONOCLONAL ANTIBODY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER</i> .....	86
<i>TABLE 28 (CONTINUED)</i> .....	87
<i>TABLE 28 (CONTINUED)</i> .....	88
Abegrin (formerly Vitaxin) .....	89
Avastin .....	89
Campath/MabCampath.....	90
CP-675,206 .....	90
Denosumab .....	90
Herceptin .....	90
HuMax-CD4 .....	90
HuMax-CD20 .....	90
HuMax-EGFr .....	90
MDX-010 .....	91
Nimotuzumab .....	91
OvaRex .....	91
Pemtumomab.....	92
Rencarex.....	92
Rituxan/MabThera .....	92
VACCINES.....	93
<i>TABLE 29 TUMOR ANTIGENS USED IN CANCER VACCINES</i> .....	94
TYPES OF CANCER VACCINES .....	95
Whole-cell Vaccines .....	95
Antigen/Adjuvant Vaccines .....	95
Idiotypic Vaccines .....	95
Autologous versus Allogenic Vaccines .....	95
Dendritic Cell Vaccines .....	96
Synthetic Cell Protein Antigens .....	96

Gangliosides.....	97
Heat Shock Proteins .....	97
CANCER VACCINES ON THE WORLDWIDE MARKET .....	97
Gardasil.....	98
M-Vax.....	98
Melacine .....	99
OncoVax .....	99
THE MARKET FOR CANCER VACCINES .....	99
TABLE 30 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION .....	100
TABLE 31 GLOBAL MARKET FORECAST FOR CANCER VACCINES, BY TECHNOLOGY, THROUGH 2012 (\$ MILLIONS).....	100
FIGURE 6 PERCENTAGE OF GLOBAL MARKET HELD BY AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, 2007 AND 2012 (%).....	101
CANCER VACCINES IN DEVELOPMENT.....	101
TABLE 32 SELECTED CANCER VACCINES IN PHASE III OR LATER TRIALS.....	102
TABLE 32 (CONTINUED).....	103
TABLE 33 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT.....	104
Allovectin-7 .....	104
Allovectin-7 (Continued).....	105
BiovacID .....	106
Cervarix .....	106
DCVax-Brain .....	107
DCVax-Prostate .....	107
GMK.....	108
GVAX Prostate Vaccine.....	109
IGN101.....	110
Insegia.....	110
Insegia (Continued).....	111
Insegia (Continued).....	112
M-Vax.....	113
Melacine .....	114
MyVax Personalized Immunotherapy .....	114
Myvax Personalized ... (Continued).....	115
Oncophage.....	116
OncoVax .....	117
Panvac-VF.....	118
Sipuleucel-T .....	119
Stimuvax .....	120
TG 4001.....	121
TG 1042.....	122



Theratope .....	122
OTHER IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER .....	123
MARKETED PRODUCTS .....	123
Gleevec .....	123
Iressa .....	124
Nexavar .....	124
Revlimid .....	125
Sprycel .....	125
Sutent .....	126
Tarceva .....	127
Thalomid .....	127
Velcade .....	127
The Market for Other Immunotherapy Products for the Treatment of Cancer .....	128
<i>TABLE 34 GLOBAL MARKET FORECAST FOR OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2012 (\$ MILLIONS)</i> .....	128
PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF CANCER .....	128
<i>TABLE 35 OTHER IMMUNOTHERPAY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER</i> .....	129
<i>TABLE 28 (CONTINUED)</i> .....	130
<i>TABLE 28 (CONTINUED)</i> .....	131
Advexin .....	131
BAY 43-9006 .....	131
Ceplene .....	132
Dacogen .....	132
Efaproxyn .....	132
Genasense .....	133
Hycamptin .....	133
INGN 241 .....	134
Junovan .....	134
Nexavar .....	134
Onconase .....	134
Orathecin .....	135
Pixantrone .....	135
PTK787 .....	135
Telcyta .....	136
Thymitaq .....	136
Torisel .....	136
Tykerb/Tycerb .....	137
Velcade .....	137
Zarnestra .....	137

Zarnestra (Continued) .....	138
INDUSTRY .....	139
BLOCKBUSTER DRUGS ON THE WORLDWIDE	
PHARMACEUTICAL MARKET APPROACH 100 .....	139
U.S. PHARMACEUTICAL INDUSTRY GROWTH TO INCREASE	
SLIGHTLY .....	140
MORE MERGERS, ACQUISITIONS AND LICENSING .....	140
MORE MERGERS, ACQUISITIONS AND ... (Continued) .....	141
BIOGENERICS—THE NEXT REVOLUTION .....	142
BIOGENERICS—THE NEXT ... (Continued) .....	143
COMPANY PROFILES .....	144
ABGENIX, INC. ....	144
BUSINESS OVERVIEW .....	144
FINANCIAL INFORMATION .....	144
PRODUCTS .....	144
XenoMouse and XenoMax Technologies .....	145
Technology Advantages .....	146
Technology Advantages (Continued) .....	147
CORPORATE STRATEGY .....	148
ALFACELL CORPORATION .....	149
BUSINESS OVERVIEW .....	149
FINANCIAL INFORMATION .....	149
PRODUCTS .....	149
CORPORATE STRATEGY .....	150
AMGEN, INC. ....	150
BUSINESS OVERVIEW .....	150
FINANCIAL INFORMATION .....	151
PRODUCTS .....	151
<b><i>TABLE 36 AMGEN'S PRODUCTS IN PHASE II OR LATER</i></b>	
<b><i>DEVELOPMENT</i></b> .....	151
CORPORATE STRATEGY .....	152
ANTIGENICS INC. ....	152
BUSINESS OVERVIEW .....	152
FINANCIAL INFORMATION .....	153
PRODUCTS .....	153
<b><i>TABLE 37 ANTIGENICS' PRODUCT PIPELINE</i></b> .....	153
CORPORATE STRATEGY .....	153
AVAX TECHNOLOGIES, INC. ....	154
BUSINESS OVERVIEW .....	154
PRODUCTS .....	154
CORPORATE STRATEGY .....	155
BIOGEN IDEC, INC. ....	156
BUSINESS OVERVIEW .....	156

FINANCIAL INFORMATION.....	156
PRODUCTS .....	157
CORPORATE STRATEGY .....	157
BIOMIRA INC.....	158
EDMONTON R&D PARK.....	158
BUSINESS OVERVIEW.....	159
FINANCIAL INFORMATION.....	159
PRODUCTS .....	159
CORPORATE STRATEGY .....	160
CHIRON CORPORATION .....	160
BUSINESS OVERVIEW.....	160
FINANCIAL INFORMATION.....	160
LEADING PRODUCTS.....	161
CORPORATE STRATEGY .....	161
GENENTECH, INC. ....	161
BUSINESS OVERVIEW.....	161
FINANCIAL INFORMATION.....	162
PRODUCTS .....	162
CORPORATE STRATEGY .....	163
<i>TABLE 38 SELECTED PRODUCTS FROM WHICH GENENTECH</i>	
<i>RECEIVES ROYALTIES.....</i>	<i>163</i>
<i>TABLE 38 (CONTINUED).....</i>	<i>164</i>
<i>TABLE 39 SELECTED ADDITIONAL PRODUCTS FROM WHICH</i>	
<i>GENENTECH RECEIVES ROYALTIES .....</i>	<i>165</i>
GENMAB A/S.....	165
BUSINESS OVERVIEW.....	165
FINANCIAL INFORMATION.....	165
PRODUCTS .....	166
CORPORATE STRATEGY .....	166
GENZYME CORPORATION.....	167
BUSINESS OVERVIEW.....	167
FINANCIAL INFORMATION.....	167
PRODUCTS .....	167
CORPORATE STRATEGY .....	167
GLAXOSMITHKLINE PLC .....	168
BUSINESS OVERVIEW.....	168
FINANCIAL INFORMATION.....	168
PRODUCTS .....	169
IMCLONE SYSTEMS, INC.....	169
BUSINESS OVERVIEW.....	169
FINANCIAL INFORMATION.....	169
PRODUCTS .....	169
<i>TABLE 40 IMCLONE SYSTEMS' PRODUCT PIPELINE.....</i>	<i>170</i>
CORPORATE STRATEGY .....	170

IMMUNOMEDICS, INC.....	171
BUSINESS OVERVIEW.....	171
FINANCIAL INFORMATION.....	171
PRODUCTS.....	171
<i>TABLE 41 IMMUNOMEDICS' THERAPEUTIC PRODUCT PIPELINE.....</i>	<i>172</i>
<i>TABLE 41 (CONTINUED).....</i>	<i>173</i>
CORPORATE STRATEGY.....	173
MEDAREX, INC. ....	174
BUSINESS OVERVIEW.....	174
FINANCIAL INFORMATION.....	174
PRODUCTS.....	174
<i>TABLE 42 MEDAREX'S PRODUCT PIPELINE.....</i>	<i>175</i>
CORPORATE STRATEGY.....	175
MEDIMMUNE, INC. ....	176
BUSINESS OVERVIEW.....	176
FINANCIAL INFORMATION.....	176
LEADING PRODUCTS.....	176
Leading Products (Continued).....	177
<i>TABLE 43 MEDIMMUNE'S PRODUCTS IN PHASE II OR LATER</i>	
<i>DEVELOPMENT.....</i>	<i>178</i>
CORPORATE STRATEGY.....	178
MERCK & COMPANY, INC.....	178
BUSINESS OVERVIEW.....	179
FINANCIAL INFORMATION.....	179
PRODUCTS.....	179
CORPORATE STRATEGY.....	179
MILLENNIUM PHARMACEUTICALS, INC.....	180
BUSINESS OVERVIEW.....	180
FINANCIAL INFORMATION.....	180
PRODUCTS.....	181
<i>TABLE 44 MILLENNIUM'S PRODUCTS IN PHASE II OR LATER</i>	
<i>DEVELOPMENT.....</i>	<i>181</i>
CORPORATE STRATEGY.....	181
NORTHWEST BIOTHERAPEUTICS, INC.....	181
BUSINESS OVERVIEW.....	182
FINANCIAL INFORMATION.....	182
PRODUCTS.....	182
<i>TABLE 45 NORTHWEST BIOTHERAPEUTICS' PRODUCT PIPELINE.....</i>	<i>182</i>
CORPORATE STRATEGY.....	183
PFIZER CORPORATION.....	183
BUSINESS OVERVIEW.....	183
FINANCIAL INFORMATION.....	184
PRODUCTS.....	184
CORPORATE STRATEGY.....	184

Corporate Strategy (Continued).....	185
PROGENICS PHARMACEUTICALS, INC. ....	186
BUSINESS OVERVIEW.....	186
FINANCIAL INFORMATION.....	186
LEADING PRODUCTS.....	186
<i>TABLE 46 PROGENICS' PRODUCT PIPELINE .....</i>	<i>187</i>
CORPORATE STRATEGY .....	187
PROTEIN DESIGN LABS.....	188
BUSINESS OVERVIEW.....	188
FINANCIAL INFORMATION.....	188
PRODUCTS.....	188
<i>TABLE 47 PROTEIN DESIGN LABS' PRODUCTS IN PHASE II OR</i>	
<i>LATER.....</i>	<i>189</i>
CORPORATE STRATEGY .....	189
TRANSGENE S/A.....	190
BUSINESS OVERVIEW.....	190
FINANCIAL INFORMATION.....	190
PRODUCTS.....	190
CORPORATE STRATEGY .....	191
VIREXX MEDICAL CORPORATION.....	191
BUSINESS OVERVIEW.....	191
FINANCIAL INFORMATION.....	192
PRODUCTS.....	192
CORPORATE STRATEGY .....	192